Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 fitusiran crossover study in severe hemophilia A or B
jRCT2001230001Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Annualized bleeding rate in the fitusiran primary efficacy period. Started Aug 2023; status: active, not recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2001230001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2001230001.